(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ATS 2025 International Conference in San Francisco, CA.
Efzofitimod, the company's first-in-class biologic immunomodulator, is in clinical development for the treatment of interstitial lung diseases or ILD such as pulmonary sarcoidosis.
The posters will showcase data from the ongoing Phase 3 EFZO-FIT study, focusing on trial design, patient characteristics, and real-world treatment patterns in pulmonary sarcoidosis.
The presentation includes the EFZO-FIT trial design and patient characteristics, which will be presented on May 19, 2025; real-world treatment patterns in pulmonary sarcoidosis, set for May 18, 2025; and an analysis of the incidence and prevalence of pulmonary sarcoidosis in the U.S., scheduled for May 20, 2025.
These posters will provide important insights into the ongoing Phase 3 EFZO-FIT study and the broader landscape of pulmonary sarcoidosis treatment.
Efzofitimod aims to resolve inflammation in the lungs without immune suppression, potentially preventing fibrosis progression.
The company expects topline results from the Phase 3 study in the third quarter of 2025.
These findings represent a significant step in developing a novel treatment for pulmonary sarcoidosis and other forms of ILD, conditions with limited therapeutic options.
Currently, ATYR is trading at $3.51 up by 1.44%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
